Physician profile
Jonathan A Cabin
NPI 1114244084
$34,787.63
in general payments reported to CMS, 2019-2025
13 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $124 · 2021: $37.08 · 2022: $33K · 2023: $272 · 2024: $686 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $34,079.19 | 2019-2025 | Dysport |
| Merz North America, INC. | $187.08 | 2024-2025 | |
| Allergan, INC. | $153.01 | 2019-2020 | |
| Stryker Corporation | $84.03 | 2019 | |
| Revance Therapeutics, INC. | $75.18 | 2024-2025 | Daxxify |
| Almirall LLC | $42.94 | 2023-2024 | Klisyri, Seysara |
| Leo Pharma INC. | $31.33 | 2023 | Adbry |
| Incyte Corporation | $25.80 | 2024 | Opzelura |
| Baxter Healthcare | $24.99 | 2025 | Artiss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.87 | 2023 | Arazlo, Duobrii, Jublia |
| Epi Health, LLC | $23.81 | 2021 | |
| Lilly USA, LLC | $23.13 | 2023 | Olumiant, Taltz |
| Janssen Biotech, INC. | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cabin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.